Ranger II SFA Pivotal Trial1

12-Month results from the Ranger II SFA Pivotal Trial, a prospective, multi-center, randomized controlled trial

(3:1 Ranger DCB vs. uncoated balloon). 
Primary safety endpoint was freedom from MAE and primary effectiveness endpoint was binary primary patency.

12-Month Primary Patency
1. RANGER II SFA Pivotal Trial 12-Month Results presented by Marianne Brodmann. LINC 2020. 12-Month Primary Endpoints: Binary Primary Patency = 82.9% for Ranger DCB and 66.3% for PTA (p= <0.0017). Freedom from Major Adverse Events = 94.1% for Ranger DCB and 83.5% for PTA (Pnon-inferiority <0.0001)
2. Kaplan-Meier Estimate: Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
* At risk denotes the number subjects entered in the calculation at the time interval.
** Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
  
RESULTS RANGER PTA p-value
Primary Safety Endpoint
(Freedom from MAE)
94.1%
(241/256)
83.5%
(76/91)
Pnon-inferiority<0.0001
Primary Effectiveness Endpoint
(Binary Primary Patency)
82.9%
(194/234)
66.3%
(57/86)
0.0017
 
  

CD-TLR & Mortality

Compared to PTA, Ranger demonstrated:

  • Significantly lower TLR
  • No difference in mortality
CD-TLR and Mortality charts
3. At risk denotes the number subjects entered in the calculation at the time interval.
4. Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.

Ranger PK Substudy5

Ranger PK Substudy

Study Method

  • Protocol required blood draws: Baseline, 10 minutes, 30 minutes 1, 3, 6, 24 or 48 hours.
  • All 12 patients received Ranger DCB
  • Average number of DCBs used per patient: 1.75
  • Measurable level is 1.0 ng/ml.

5. RANGER II SFA PK Substudy presented by Ravish Sachar, MD. VIVA 2019.

CAUTION: Ranger is an Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale. 
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top